Azitra (AZTR) Total Non-Current Liabilities (2022 - 2025)
Azitra's (AZTR) quarterly Total Non-Current Liabilities came in at $1.2 million in Q4 2025, down 26.26% YoY from $1.7 million in Q4 2024, and down 39.43% on a QoQ basis from $2.0 million in Q3 2025.
Azitra (AZTR) Total Non-Current Liabilities (2022 - 2025) Analysis & Trends
Azitra (AZTR) has 4 years of Total Non-Current Liabilities data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 26.26% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 26.26% YoY) and the FY2025 annual result came in at $1.2 million, down 26.26% from the prior year.
- Total Non-Current Liabilities slipped to $1.2 million in Q4 2025, from $2.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $9.7 million in Q4 2022 to a low of $1.2 million in Q4 2025.
- A 4-year average of $2.5 million and a median of $1.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 77.58% — and 2025, when it advanced 17.59%.
- Tracing AZTR's Total Non-Current Liabilities over 4 years: stood at $9.7 million in 2022, then tumbled by 77.58% to $2.2 million in 2023, then slipped by 23.39% to $1.7 million in 2024, then declined by 26.26% to $1.2 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $1.2 million (Q4 2025), $2.0 million (Q3 2025), and $1.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Azitra | 2.44 Mn | 2.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.22 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 2.17 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 2.43 Mn |
| Dec 31, 2022 | 9.66 Mn |